DeutschNewstral
Article
Forbes on 2023-10-25 11:38
RSV Vaccine Shows Hopeful Early Results In 50 To 59-Year-Olds, GSK Says
Related news
- GSK Boosts Profit Forecasts After ‘Outstanding’ RSV Vaccine LaunchForbes
GSK hikes outlook after launch of new RSV vaccineexpressandstar.com
GSK Sues Pfizer for Patent Infringement over RSV Vaccinejdsupra.com- BFDA Advisers Had Questions On Pfizer's RSV Vaccine. GSK Could Be First To Market.5 min readbarrons.com
World's first RSV vaccine approved by FDA — breakthrough 60 years in the makingNew York Post- BGSK Reports a Win for Its RSV Vaccine3 min readbarrons.com
- FGSK PLC: GSK bets on blockbuster RSV jab to power recoveryft.com
Signed GSK Document Admits Vaccine Caused Autisminfowars.com- FGSK ships Ebola vaccine to west Africaft.com
- FGSK poaches key vaccine executive from Pfizerft.com
- MFDA approves Moderna RSV vaccine for seniorsmvtelegraph.com
1st RSV vaccine for pregnant women approvednwaonline.com
U.S. government awards $2.1B to Sanofi-GSK coronavirus vaccinePOLITICO- DState approves vaccine for six month-oldsdchieftain.com
- FDA advisers support GSK’s RSV vaccinenwaonline.com
- FSanofi and GSK to supply UK with Covid-19 vaccineft.com
- GSK raises profit guidance as vaccine demand growsexpressandstar.com